Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.32 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | KMO | O15229 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL5622303 | 0.90 | MEN1 (0.39) | MEN1MAPTKMT2AMAPK9MAPK10 | |
| SCHEMBL3680239 | 0.78 | MEN1 (0.47) | MEN1MAPTKMT2A | |
| SCHEMBL27570732 | 0.76 | MEN1 (0.42) | MEN1MAPTKMT2A | |
| SCHEMBL25991063 | 0.76 | MEN1 (0.42) | MEN1MAPTKMT2AKMO | |
| SCHEMBL25786474 | 0.76 | MEN1 (0.42) | MEN1MAPTKMT2AKDM4ELMNA | |
| SCHEMBL22169127 | 0.75 | TRPV3 (0.48) | MEN1MAPTKMT2ACLK4LRRK2 | |
| SCHEMBL501903 | 0.74 | — | — | |
| SCHEMBL670100 | 0.74 | MAPT (0.32) | MAPT | |
| SCHEMBL5258991 | 0.73 | FFAR1 (0.36) | FFAR1 | |
| SCHEMBL14404281 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470686-B2 | Method of inhibiting the expression and/or the activity of JNK | LABORATOIRES SERONO SA (CH) | 2008-12-30 | — | — | US | claimed |
| CN-1252067-C | Benzazole derivatives and their use as JNK modulators | APPLIED RESEARCH SYSTEMS (AN) | 2006-04-19 | — | — | CN | claimed |
| CN-1433414-A | Benzazole derivatives and their use as JNK modulators | APPLIED RESEARCH SYSTEMS (NL) | 2003-07-30 | — | — | CN | claimed |
| CN-112812105-A | Aminopyridyloxypyrazole derivative and preparation method and application thereof | 苏州阿尔脉生物科技有限公司 | 2021-05-18 | — | — | CN | disclosed |
| US-20070123530-A1 | Azole methylidene cyanide derivatives and their use as protein kinase modulators | MERCK SERONO SA (CH) | 2007-05-31 | — | — | US | disclosed |
| CN-1310911-C | Piperazine benzothiazoles as therapeutics for cerebral ischemic and CNS disorders | APPLIED RESEARCH SYSTEMS (AN) | 2007-04-18 | — | — | CN | disclosed |
| CN-1252067-C | Benzazole derivatives and their use as JNK modulators | APPLIED RESEARCH SYSTEMS (AN) | 2006-04-19 | — | — | CN | disclosed |
| CN-1662528-A | Piperazine benzothiazoles as therapeutics for cerebral ischemic and CNS disorders | APPLIED RESEARCH SYSTEMS (AN) | 2005-08-31 | — | — | CN | disclosed |
| CN-1433414-A | Benzazole derivatives and their use as JNK modulators | APPLIED RESEARCH SYSTEMS (NL) | 2003-07-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123530-A1 | Azole methylidene cyanide derivatives and their use as protein kinase modulators | PRKACA, CSNK1A1, PRKACG | MEN1 1553/4885MAPT 3106/4885KMT2A 1939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.